Researchers at Queen's University in Belfast and University College London have discovered that a drug, originally developed to treat cardiovascular disease, has the potential to reduce diabetes-related blindness.
According to recent WHO global estimates, 422 million people worldwide have diabetes, and one of the most common complications of this disease is vision loss. Diabetic Macular Edema occurs in approximately 7 per cent of patients with diabetes and is one of the most common causes of blindness in the western world.
Currently, the most common treatments for patients with Diabetic Macular Edema is an injection of a drug directly into to the eye every four to six weeks. The therapy is very expensive and doesn't work for about half of all patients with Diabetic Macular Edema.
Read the full story: